View More
Learn about the integration of biosimilars into oncology care with this expert-authored module reviewing biosimilar fundamentals, the regulatory review process for biosimilars, current FDA-approved biosimilars, and key trial data on biosimilars in breast and lung cancers.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Registered Nurses:
1.0 Nursing contact hour
Pharmacists:
1.0 contact hour (0.1 CEUs)
Released: April 20, 2020
Expired:
No longer available for credit
Download these slides with expert recommendations on the approval and integration of oncology biosimilars for clinical practice.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Released: April 20, 2020
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.